PMID- 10556259
OWN - NLM
STAT- MEDLINE
DCOM- 20000118
LR  - 20190513
IS  - 1462-0324 (Print)
IS  - 1462-0324 (Linking)
VI  - 38
IP  - 11
DP  - 1999 Nov
TI  - Serum levels of matrix metalloproteinase-3 in relation to the development of 
      radiological damage in patients with early rheumatoid arthritis.
PG  - 1081-7
AB  - OBJECTIVE: To evaluate the significance of serum matrix metalloproteinase-3 
      (MMP-3) levels in relation to the development of radiological damage (X-ray 
      damage) in early rheumatoid arthritis (RA). METHODS: Serum MMP-3 levels were 
      measured in 46 healthy controls (CTRL), 19 osteoarthritis (OA) and 78 RA patients 
      with joint symptoms for <1 yr at presentation (T0): 48 patients without and 30 
      with X-ray damage at T0. Serum MMP-3, measured by ELISA, and X-ray damage, scored 
      according to Sharp's method, were assessed at 0, 6, 12 and 24 months. RESULTS: 
      MMP-3 levels in CTRL and OA were low or undetectable with no differences between 
      the groups (P=0.19). Levels in RA were higher than in CTRL (P<0.01). Initial 
      MMP-3 levels in patients with X-ray damage at T0 (n=30) were higher than the 
      levels in patients without any X-ray damage during follow-up (n=19) (P<0.01), but 
      were not different from those in patients who developed X-ray damage during the 
      study (n=29) (P=0.11). In the patients without X-ray damage at T0, there was a 
      significant correlation between MMP-3 at T0 and the total X-ray damage after 6 
      months (r=0.34, P=0.02) and 12 months (r=0.32, P=0.03). This correlation was 
      almost exclusively determined by joint space narrowing in the Sharp score. 
      CONCLUSION: The serum MMP-3 level seems to be an indicator for the development of 
      radiological damage in patients with early RA and appears to be particularly 
      indicative of cartilage degradation.
FAU - Posthumus, M D
AU  - Posthumus MD
AD  - Department of Rheumatology, University Hospital Groningen, The Netherlands.
FAU - Limburg, P C
AU  - Limburg PC
FAU - Westra, J
AU  - Westra J
FAU - Cats, H A
AU  - Cats HA
FAU - Stewart, R E
AU  - Stewart RE
FAU - van Leeuwen, M A
AU  - van Leeuwen MA
FAU - van Rijswijk, M H
AU  - van Rijswijk MH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Biomarkers)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Arthritis, Rheumatoid/blood/*diagnostic imaging/*enzymology
MH  - Biomarkers
MH  - C-Reactive Protein/metabolism
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Prospective Studies
MH  - Radiography
EDAT- 1999/11/11 00:00
MHDA- 1999/11/11 00:01
CRDT- 1999/11/11 00:00
PHST- 1999/11/11 00:00 [pubmed]
PHST- 1999/11/11 00:01 [medline]
PHST- 1999/11/11 00:00 [entrez]
AID - 10.1093/rheumatology/38.11.1081 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 1999 Nov;38(11):1081-7. doi: 
      10.1093/rheumatology/38.11.1081.